Patents Assigned to Edgemont Pharmaceuticals LLC
  • Alcohol-resistant oral pharmaceutical compositions of lorazepam
    Patent number: 11806433
    Abstract: Described herein are alcohol-resistant oral pharmaceutical compositions and dosage forms that exhibit reduced drug release in the presence of alcohol. The compositions comprise a substrate comprising a controlled release formulation of lorazepam and an alcohol-resistant coating surrounding the substrate.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: November 7, 2023
    Assignee: EDGEMONT PHARMACEUTICALS, LLC TRUST
    Inventors: Douglas Saltel, Michael Vachon
  • Sustained release formulations of lorazepam
    Publication number: 20160228378
    Abstract: A pharmaceutical composition for delivering lorazepam in a prolonged fashion is achieved with prolonged release lorazepam pharmaceutical beads. The composition typically contains sustained release lorazepam beads and delayed sustained release lorazepam beads. The composition can provide once daily dosing that maintains 24 hour therapeutic effect under steady state conditions.
    Type: Application
    Filed: December 23, 2015
    Publication date: August 11, 2016
    Applicant: Edgemont Pharmaceuticals, LLC
    Inventors: Douglas A. Saltel, Michael Vachon
  • Sustained release formulations of lorazepam
    Patent number: 8999393
    Abstract: A pharmaceutical composition for delivering lorazepam in a prolonged fashion is achieved with prolonged release lorazepam pharmaceutical beads. The composition typically contains sustained release lorazepam beads and delayed sustained release lorazepam beads. The composition can provide once daily dosing that maintains 24 hour therapeutic effect under steady state conditions.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: April 7, 2015
    Assignee: Edgemont Pharmaceuticals LLC
    Inventors: Douglas A. Saltel, Michael Vachon